Evidence map›Paper›PMID 31619184›Full record

Trial reportBMC geriatrics2019

A randomized controlled efficacy study of the Medido medication dispenser in Parkinson's disease.

K Hannink, L Ter Brake, N G M Oonk, A A Wertenbroek, M Piek, L Vree-Egberts, M J Faber, J van der Palen, L D Dorresteijn

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC geriatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

K HanninkDepartment of Neurology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, the Netherlands.
L Ter BrakeDepartment of Neurology, Ziekenhuis Groep Twente, Almelo, the Netherlands.
N G M OonkDepartment of Neurology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, the Netherlands.
A A WertenbroekDepartment of Neurology, Ziekenhuis Groep Twente, Almelo, the Netherlands.
M PiekDepartment of Neurology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, the Netherlands.
L Vree-EgbertsDepartment of Neurology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, the Netherlands.
M J FaberRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
J van der PalenDepartment of Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands.
L D DorresteijnDepartment of Neurology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, the Netherlands. l.dorresteijn@mst.nl.ORCID 0000-0001-8540-7624
Medisch Spectrum Twente · NLZiekenhuis Groep Twente · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComplex medication schedules in Parkinson's disease (PD) result in lower therapy adherence, which contributes to suboptimal therapy and clinical deterioration. Medication reminder systems might improve therapy adherence and subsequently improve symptoms of PD. This randomized controlled study assessed the effect of the electronic medication dispenser Medido on physical disability in PD, as a proxy for changes in therapy adherence.x

methodsEighty-seven patients were randomized into the Medido group or control group. The primary outcome of physical disability was measured by the AMC Linear Disability Scale (ALDS). Secondary outcomes were quality of life (QoL) (PDQ-39), health status (EQ5D-5L, VAS), non-motor symptoms (NMS-Quest), and QoL of the caregiver (PDQ-carer). Measurements were performed at baseline, and after 3 and 6 months follow-up.

resultsWhen using the Medido, a non-significant improvement of 3.0 points (95% CI -5.6;11.6) was seen in ALDS. The exploratory subgroup Hoehn & Yahr classification (H&Y) > 2.5 improved significantly on ALDS with 14.7 points (95% CI -28.5;-0.9, p = 0.029 for group x time interaction). QoL deteriorated with 1.0 point in PDQ-39 (p = 0.01 for group x time interaction) in favor of the control group. Non-significant differences were observed for VAS (0.4 points, p = 0.057) and NMS-Quest (1.3 points, p = 0.095) in favor of the Medido group. No changes over time were observed in EQ5D-5L and PDQ-carer.

conclusionsBased on these data, no firm conclusion can be drawn, but use of the Medido medication dispenser may result in a clinical improvement of physical disability and seems particularly appropriate for more severe patients.

trial registrationNTR3917 . Registered 19 March 2013.

Indexed as

AgedAged, 80 and overAntiparkinson AgentsCaregiversDrug Administration ScheduleDrug Delivery SystemsFemaleFollow-Up StudiesHealth StatusHumansMaleMedication AdherenceMiddle AgedParkinson DiseasePersons with DisabilitiesQuality of LifeAntiparkinson AgentsElectronic medication dispenserParkinson’s diseasePhysical disabilityQuality of lifeTherapy adherence

Identifiers

PMID31619184
PMCPMC6796399
OpenAlexW2980475416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.